LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis Published: 22 Oct, 2021 | Tags: LEO, Tralokinumab, P-III, ECZTRA 6 Trial, […]readmore
Tags : BehaVR
Shots: BehaVR to receive $5M up front, ~$18M in development milestone and R&D support along with commercial & operational support fees and is eligible to receive $140M in milestone upon […]readmore